{"entity":{"id":"legend-biotech","kind":"company","name":"Legend Biotech","aka":[],"tldr":"Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.","summary":"Legend Biotech, based in Somerset, New Jersey, and Nanjing and listed as LEGN, is the Chinese-origin developer of Carvykti, or ciltacabtagene autoleucel, the most effective myeloma CAR-T, in partnership with Johnson & Johnson. Cilta-cel was proved in LEGEND-2, CARTITUDE-1 and CARTITUDE-4, and the company is developing solid-tumour CAR-Ts including LB1908 against Claudin 18.2 and a DLL3 programme, with Fangliang Zhang among the people linked. OnCo links it to multiple myeloma, to the cilta-cel drug record and to the Comprehensive Cancer Center Mainfranken. Whether Legend can take a solid-tumour CAR-T as far as its myeloma product is the open question. Ciltacabtagene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.legendbiotech.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["ciltacabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Somerset, NJ / Nanjing","country":"US","companyType":"cell-therapy","website":"https://www.legendbiotech.com","ticker":"LEGN","investors":[],"funding":[]},"route":"/companies/legend-biotech/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"drug":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"trial":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/"},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/"}],"person":[{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/"}],"paper":[{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/"},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/"}],"institution":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/"}],"technology":[{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"}]}}